Free Trial
NYSEAMERICAN:AZTR

Azitra 8/12/2024 Earnings Report

Azitra logo
$0.75 -0.17 (-18.87%)
Closing price 08/25/2025 04:10 PM Eastern
Extended Trading
$0.72 -0.03 (-3.75%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azitra EPS Results

Actual EPS
-$18.25
Consensus EPS
-$17.25
Beat/Miss
Missed by -$1.00
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Azitra's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Azitra Earnings Headlines

AZTR: Second Quarter Update
GENIUS Act: Cancel Your Money?
They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—not the government—have been handed control of a new class of programmable money. It’s not called a CBDC, but it acts just like one. Your spending could be tracked, limited, or even frozen—whether you opt in or not. Once this system becomes the default, escape won’t be easy.tc pixel
Azitra, Inc. Announces Reverse Stock Split
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat